Suraxavir marboxil

玛舒拉沙韦

Report date: 2026/03/24 20:00:35
NME

Base Information

Drug NameSuraxavir marboxil
Drug Alias Name伊速达YisudaGP-681
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolymerase acidic protein inhibitors
TargetsPolymerase acidic protein
Therapy Area/IndicationsInfluenza A virus infectionsSolid tumoursacute influenza +[7] 
Global Approved IndicationsInfluenza A virus infectionsInfluenza B virus infection
Approved Indications in ChinaInfluenza A virus infectionsInfluenza B virus infection
Original Approved Country/TerritoryMainland China
Original Approved Date2025/03/25
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangxi Kvvit Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangxi Kvvit Pharmaceutical Co LtdCapital Medical UniversityGinkgo Tree Pharmaceutical (Suzhou) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infectionsSolid tumoursacute influenza +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A